Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer

G. Pizzocaro, M. Pasi, R. Salvioni, F. Zanoni, A. Milani, L. Piva

Research output: Contribution to journalArticle

Abstract

Thirty-two consecutive patients with pretreated germinal testis cancer received 3 to 4 inductions of cisplatin and etoposide therapy (PE). Patients not pretreated, or only partially pretreated with bleomycin (B), also received this drug for a maximum of 12 doses. Sixteen patients underwent secondary surgery for the removal of residual masses. Twelve (37.5%) entered complete remission (CR) with chemotherapy alone, and an additional 9 cases (28%) were rendered tumor-free by surgery. The 21 disease-free patients (65.5%) received 2 further inductions and no maintenance. Toxicity was moderate, and 1 of the 16 patients who underwent surgery died postoperatively of pulmonary embolism. After a median follow-up period of 26 months (range, 9-60), 2 patients have died in CR and 15 (47%) are currently alive and have been continuously disease-free. The major determinant of tumor response was prior therapy. Eleven of 14 (78%) patients who were not pretreated with cisplatin achieved a continuous disease-free status versus only 4 of the 18 pretreated patients (22%, P <0.01). In this set of cases, complete responders to prior PVB therapy did better than incomplete responders treated for tumor progression. It can be concluded that normal-dose PE ± B therapy, followed by surgical resection of the residual tumor, is a satisfactory salvage therapy in patients not pretreated with cisplatin and is also active in complete responders to prior PVB therapy.

Original languageEnglish
Pages (from-to)2399-2403
Number of pages5
JournalCancer
Volume56
Issue number10
DOIs
Publication statusPublished - 1985

Fingerprint

Salvage Therapy
Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
Residual Neoplasm
Etoposide
Cisplatin
Therapeutics
Neoplasms
Bleomycin
Pulmonary Embolism
Maintenance
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer. / Pizzocaro, G.; Pasi, M.; Salvioni, R.; Zanoni, F.; Milani, A.; Piva, L.

In: Cancer, Vol. 56, No. 10, 1985, p. 2399-2403.

Research output: Contribution to journalArticle

@article{27ef87750d7b47b2ae451d55d2a94363,
title = "Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer",
abstract = "Thirty-two consecutive patients with pretreated germinal testis cancer received 3 to 4 inductions of cisplatin and etoposide therapy (PE). Patients not pretreated, or only partially pretreated with bleomycin (B), also received this drug for a maximum of 12 doses. Sixteen patients underwent secondary surgery for the removal of residual masses. Twelve (37.5{\%}) entered complete remission (CR) with chemotherapy alone, and an additional 9 cases (28{\%}) were rendered tumor-free by surgery. The 21 disease-free patients (65.5{\%}) received 2 further inductions and no maintenance. Toxicity was moderate, and 1 of the 16 patients who underwent surgery died postoperatively of pulmonary embolism. After a median follow-up period of 26 months (range, 9-60), 2 patients have died in CR and 15 (47{\%}) are currently alive and have been continuously disease-free. The major determinant of tumor response was prior therapy. Eleven of 14 (78{\%}) patients who were not pretreated with cisplatin achieved a continuous disease-free status versus only 4 of the 18 pretreated patients (22{\%}, P <0.01). In this set of cases, complete responders to prior PVB therapy did better than incomplete responders treated for tumor progression. It can be concluded that normal-dose PE ± B therapy, followed by surgical resection of the residual tumor, is a satisfactory salvage therapy in patients not pretreated with cisplatin and is also active in complete responders to prior PVB therapy.",
author = "G. Pizzocaro and M. Pasi and R. Salvioni and F. Zanoni and A. Milani and L. Piva",
year = "1985",
doi = "10.1002/1097-0142(19851115)56:10<2399::AID-CNCR2820561010>3.0.CO;2-V",
language = "English",
volume = "56",
pages = "2399--2403",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer

AU - Pizzocaro, G.

AU - Pasi, M.

AU - Salvioni, R.

AU - Zanoni, F.

AU - Milani, A.

AU - Piva, L.

PY - 1985

Y1 - 1985

N2 - Thirty-two consecutive patients with pretreated germinal testis cancer received 3 to 4 inductions of cisplatin and etoposide therapy (PE). Patients not pretreated, or only partially pretreated with bleomycin (B), also received this drug for a maximum of 12 doses. Sixteen patients underwent secondary surgery for the removal of residual masses. Twelve (37.5%) entered complete remission (CR) with chemotherapy alone, and an additional 9 cases (28%) were rendered tumor-free by surgery. The 21 disease-free patients (65.5%) received 2 further inductions and no maintenance. Toxicity was moderate, and 1 of the 16 patients who underwent surgery died postoperatively of pulmonary embolism. After a median follow-up period of 26 months (range, 9-60), 2 patients have died in CR and 15 (47%) are currently alive and have been continuously disease-free. The major determinant of tumor response was prior therapy. Eleven of 14 (78%) patients who were not pretreated with cisplatin achieved a continuous disease-free status versus only 4 of the 18 pretreated patients (22%, P <0.01). In this set of cases, complete responders to prior PVB therapy did better than incomplete responders treated for tumor progression. It can be concluded that normal-dose PE ± B therapy, followed by surgical resection of the residual tumor, is a satisfactory salvage therapy in patients not pretreated with cisplatin and is also active in complete responders to prior PVB therapy.

AB - Thirty-two consecutive patients with pretreated germinal testis cancer received 3 to 4 inductions of cisplatin and etoposide therapy (PE). Patients not pretreated, or only partially pretreated with bleomycin (B), also received this drug for a maximum of 12 doses. Sixteen patients underwent secondary surgery for the removal of residual masses. Twelve (37.5%) entered complete remission (CR) with chemotherapy alone, and an additional 9 cases (28%) were rendered tumor-free by surgery. The 21 disease-free patients (65.5%) received 2 further inductions and no maintenance. Toxicity was moderate, and 1 of the 16 patients who underwent surgery died postoperatively of pulmonary embolism. After a median follow-up period of 26 months (range, 9-60), 2 patients have died in CR and 15 (47%) are currently alive and have been continuously disease-free. The major determinant of tumor response was prior therapy. Eleven of 14 (78%) patients who were not pretreated with cisplatin achieved a continuous disease-free status versus only 4 of the 18 pretreated patients (22%, P <0.01). In this set of cases, complete responders to prior PVB therapy did better than incomplete responders treated for tumor progression. It can be concluded that normal-dose PE ± B therapy, followed by surgical resection of the residual tumor, is a satisfactory salvage therapy in patients not pretreated with cisplatin and is also active in complete responders to prior PVB therapy.

UR - http://www.scopus.com/inward/record.url?scp=0022349842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022349842&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19851115)56:10<2399::AID-CNCR2820561010>3.0.CO;2-V

DO - 10.1002/1097-0142(19851115)56:10<2399::AID-CNCR2820561010>3.0.CO;2-V

M3 - Article

C2 - 2412681

AN - SCOPUS:0022349842

VL - 56

SP - 2399

EP - 2403

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -